The challenges of quantifying the risk of serious infection with tumor necrosis factor antagonist therapy.
Leombruno
John
J
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D007239:Infections / Q000139:chemically induced*; D015201:Meta-Analysis as Topic; D012306:Risk; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha